You are here
Protocol from Annual General Meeting
23 April 2008: NorDiag ASA held today its Annual General Meeting. Attached is the protocol from the meeting, including overview over participating shareholders. In total 66,2 per cent of the share capital was represented.
All items were unanimously adopted.
Jon Frode Vaksvik stepped down from the board of directors following his own request. The following board members were reelected:
Hans Hekland, chairman
Elke Holinski Feder, board member
Robert Allnutt, board member
Gisela Sitbon, board member
Mathias Uhlen, board member
Anne-Kristin Hageløkken, board member
The Annual General Meeting decided to include establishment of a nomination committee in the articles of association. Guidelines for the nomination committee are attached to the protocol. New nomination committee was elected and includes the following members:
J. Frode Vaksvik, chairman
Ann-Kristin Hageløkken, member
Hogne I. Tyssøy, member
Contact:
CEO Mårten Wigstøl, phone 911 65775 or CFO Tone Kvåle, phone 915 19576.
About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer, as well as a test that shall contribute to optimal treatment of lung cancer patients. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com